Personalized medicine breakthrough: Lab-Grown Mini-Guts guide treatment for rare CF cases

NCT ID NCT06468527

Summary

This study tested whether a three-drug combination (Dirocaftor/Posenacaftor/Nesolicaftor) could help adults with cystic fibrosis who have rare genetic mutations not covered by existing treatments. Researchers first used patients' own lab-grown intestinal tissue samples to predict who might respond to the drugs, then tested the treatment in 41 selected participants. The main goal was to see if this personalized approach could improve lung function and validate the use of organoid screening to match patients with effective therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Integrata

    Verona, Italy

  • CHU de Nice

    Nice, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hôpital Larrey CHU Toulouse

    Toulouse, France

  • Instituto Giannina Gaslini

    Genova, Italy

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Royal Brompton Hospital

    London, United Kingdom

  • Sahlgrenska University Hospital, Gothenburg CF center

    Gothenburg, Sweden

  • UMC Utrecht

    Utrecht, Utrecht, 3584 CX, Netherlands

  • UZ Leuven

    Leuven, Vlaams-Brabant, Belgium

  • University Hospital Southampton

    Southampton, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

Conditions

Explore the condition pages connected to this study.